

AUTHOR'S CORRECTION

Pharmacokinetics and Biliary Concentrations of Fleroxacin in Cholecystectomized Patients

W. L. HAYTON, V. VLAHOV, N. BACRACHEVA, I. VIACHKI, R. PORTMANN, G. MUIRHEAD,
K. STOECKEL, AND E. WEIDEKAMM

College of Pharmacy, Washington State University, Pullman, Washington 99164-6510; Clinical Pharmacology and Clinic of Urgent Surgery, Center of Urgent Medicine, Medical Academy of Sofia, 1040 Sofia, Bulgaria; Department of Clinical Research, F. Hoffmann-La Roche Ltd., CH-4002 Basel, Switzerland; and Department of Pharmacokinetics and Metabolism, Roche Products Ltd., Welwyn Garden City, Herts AL7 3AY, Great Britain

Volume 34, no. 12, p. 2375–2380. There was no difference between the mean half-life of fleroxacin in the cholecystectomized patients and the half-life reported for healthy volunteers. The references to a difference in half-life between these two groups in the Abstract, sentence 5, and in the first paragraph of the Discussion should be ignored.